UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 36

Sortiert nach

Role of efavirenz plasma concentrations on long-term HIV suppression and immune restoration in HIV-infected children

PloS one, 2019-05, Vol.14 (5), p.e0216868-e0216868

2019

Volltextzugriff (PDF)

Borrowing information across patient subgroups in clinical trials, with application to a paediatric trial

BMC medical research methodology, 2022-02, Vol.22 (1), p.49-49, Article 49

2022

Volltextzugriff (PDF)

Dolutegravir as First- or Second-Line Treatment for HIV-1 Infection in Children

The New England journal of medicine, 2021-12, Vol.385 (27), p.2531-2543

2021

Volltextzugriff (PDF)

Expanding options of child-friendly, single-tablet regimens for young children with HIV

The lancet HIV, 2024-05, Vol.11 (5), p.e275-e276

2024

Volltextzugriff (PDF)

Nevirapine Exposure with WHO Pediatric Weight Band Dosing: Enhanced Therapeutic Concentrations Predicted Based on Extensive International Pharmacokinetic Experience

Antimicrobial Agents and Chemotherapy, 2012-10, Vol.56 (10), p.5374-5380

2012

Volltextzugriff (PDF)

Population Pharmacokinetics of Pediatric Lopinavir/Ritonavir Oral Pellets in Children Living with HIV in Africa

Clinical pharmacology and therapeutics, 2024-05, Vol.115 (5), p.1105-1113

2024

Volltextzugriff (PDF)

Simultaneous pharmacokinetic modeling of unbound and total darunavir with ritonavir in adolescents: a substudy of the SMILE trial

Antimicrobial agents and chemotherapy, 2024-02, Vol.68 (2), p.e0100423-e0100423

2024

Volltextzugriff (PDF)

Efficacy, Safety and Pharmacokinetics of Tenofovir Disoproxil Fumarate in Virologic-Suppressed HIV-infected Children Using Weight-Band Dosing

The Pediatric infectious disease journal, 2015-04, Vol.34 (4), p.392-397

2015

Volltextzugriff (PDF)

Paediatric abacavir–lamivudine fixed-dose dispersible tablets and ritonavir-boosted lopinavir granules in neonates exposed to HIV (PETITE study): an open-label, two-stage, single-arm, phase 1/2, pharmacokinetic and safety trial

The lancet HIV, 2024-02, Vol.11 (2), p.e86-e95

2024

Volltextzugriff (PDF)

Population pharmacokinetics of unbound and total dolutegravir concentrations in children aged 12 years and older: a PK substudy of the SMILE trial

Journal of antimicrobial chemotherapy, 2023-04, Vol.78 (4), p.1041-1049

2023

Volltextzugriff (PDF)

Treatment Failure in HIV-Infected Children on Second-line Protease Inhibitor-Based Antiretroviral Therapy

Clinical infectious diseases, 2015-07, Vol.61 (1), p.95-101

2015

Volltextzugriff (PDF)

A Phase II/III Trial of Lopinavir/Ritonavir Dosed According to the WHO Pediatric Weight Band Dosing Guidelines

The Pediatric infectious disease journal, 2018-02, Vol.37 (2), p.e29-e35

2018

Volltextzugriff (PDF)

Abacavir Drug Exposures in African Children Under 14 kg Using Pediatric Solid Fixed Dose Combinations According to World Health Organization Weight Bands

Journal of the Pediatric Infectious Diseases Society, 2023-11, Vol.12 (11), p.574-580

2023

Volltextzugriff (PDF)

Optimization of the strength of the efavirenz/lamivudine/abacavir fixed-dose combination for paediatric patients

Journal of antimicrobial chemotherapy, 2017-02, Vol.72 (2), p.490-495

2017

Volltextzugriff (PDF)

One dose does not fit all: revising the WHO paediatric dosing tool to include the non-linear effect of body size and maturation

The lancet child & adolescent health, 2022-01, Vol.6 (1), p.9-10

2022

Volltextzugriff (PDF)

Pharmacokinetics, safety, tolerability, and antiviral activity of dolutegravir dispersible tablets in infants and children with HIV-1 (IMPAACT P1093): results of an open-label, phase 1–2 trial

The lancet HIV, 2022-05, Vol.9 (5), p.e332-e340

2022

Volltextzugriff (PDF)

Abacavir dosing in neonates from birth to 3 months of life: a population pharmacokinetic modelling and simulation study

The lancet HIV, 2022-01, Vol.9 (1), p.e24-e31

2022

Volltextzugriff (PDF)

Rilpivirine Pharmacokinetics Without and With Darunavir/Ritonavir Once Daily in Adolescents and Young Adults

The Pediatric infectious disease journal, 2016-09, Vol.35 (9), p.e271-e274

2016

Volltextzugriff (PDF)

Prioritising the most needed paediatric antiretroviral formulations: the PADO4 list

The lancet HIV, 2019-09, Vol.6 (9), p.e623-e631

2019

Volltextzugriff (PDF)

Pharmacokinetics of Unboosted Atazanavir in Treatment-experienced HIV-infected Children, Adolescents and Young Adults

The Pediatric infectious disease journal, 2016-12, Vol.35 (12), p.1333-1335

2016

Volltextzugriff (PDF)

Efavirenz Concentrations and Probability of HIV Replication in Children

The Pediatric infectious disease journal, 2015-11, Vol.34 (11), p.1214-1217

2015

Volltextzugriff (PDF)

Pharmacokinetics of Nevirapine in HIV and Tuberculosis–coinfected Children Receiving Antiretroviral Fixed-dose Combination Tablets While Receiving Rifampicin-containing Tuberculosis Treatment and After Rifampicin Discontinuation

The Pediatric infectious disease journal, 2012-04, Vol.31 (4), p.389-391

2012

Volltextzugriff (PDF)

Plasma efavirenz concentrations and the association with CYP2B6―516G>T polymorphism in HIV―infected Thai children

Antiviral therapy, 2009, Vol.14 (3), p.315-320

2009

Volltextzugriff (PDF)

A Chewable Pediatric Fixed-dose Combination Tablet of Stavudine, Lamivudine, and Nevirapine: Pharmacokinetics and Safety Compared With the Individual Liquid Formulations in Human Immunodeficiency Virus-infected Children in Thailand

The Pediatric infectious disease journal, 2010-10, Vol.29 (10), p.940-944

2010

Volltextzugriff (PDF)

1 – 25 von 36

Suche als RSS-Feed

Aktive Filter

Nur zeigenMit Volltextzugriff

ThemaChild

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(33)

Publikationsform

Artikel
(36)

Sprache

Englisch
(36)

Erscheinungsjahr

n.n

Thema

Humans
(36)
Science & Technology
(36)
Hiv Infections - Drug Therapy
(34)
Life Sciences & Biomedicine
(33)
Female
(27)
Infectious Diseases
(27)
Male
(26)
Adolescent
(21)
Immunology
(18)
Child, Preschool
(16)
Children
(16)
Infant
(15)
Pediatrics
(15)
Pharmacokinetics
(12)
Anti-Hiv Agents - Administration & Dosage
(11)
Hiv
(11)
Anti-Hiv Agents - Therapeutic Use
(10)
Adult
(9)
Anti-Hiv Agents - Pharmacokinetics
(9)

14 weitere anzeigen...

Weniger anzeigen...

Kollektion

7 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Role of efavirenz plasma concentrations on long-term HIV suppression and immune restoration in HIV-infected children

Borrowing information across patient subgroups in clinical trials, with application to a paediatric trial

Weekends-off efavirenz-based antiretroviral therapy in HIV-infected children, adolescents and young adults (BREATHER): Extended follow-up results of a randomised, open-label, non-inferiority trial

Dolutegravir as First- or Second-Line Treatment for HIV-1 Infection in Children

Expanding options of child-friendly, single-tablet regimens for young children with HIV

Nevirapine Exposure with WHO Pediatric Weight Band Dosing: Enhanced Therapeutic Concentrations Predicted Based on Extensive International Pharmacokinetic Experience

Population Pharmacokinetics of Pediatric Lopinavir/Ritonavir Oral Pellets in Children Living with HIV in Africa

Simultaneous pharmacokinetic modeling of unbound and total darunavir with ritonavir in adolescents: a substudy of the SMILE trial

Efficacy, Safety and Pharmacokinetics of Tenofovir Disoproxil Fumarate in Virologic-Suppressed HIV-infected Children Using Weight-Band Dosing

Paediatric abacavir–lamivudine fixed-dose dispersible tablets and ritonavir-boosted lopinavir granules in neonates exposed to HIV (PETITE study): an open-label, two-stage, single-arm, phase 1/2, pharmacokinetic and safety trial

Population pharmacokinetics of unbound and total dolutegravir concentrations in children aged 12 years and older: a PK substudy of the SMILE trial

Treatment Failure in HIV-Infected Children on Second-line Protease Inhibitor-Based Antiretroviral Therapy

A Phase II/III Trial of Lopinavir/Ritonavir Dosed According to the WHO Pediatric Weight Band Dosing Guidelines

Abacavir Drug Exposures in African Children Under 14 kg Using Pediatric Solid Fixed Dose Combinations According to World Health Organization Weight Bands

Optimization of the strength of the efavirenz/lamivudine/abacavir fixed-dose combination for paediatric patients

One dose does not fit all: revising the WHO paediatric dosing tool to include the non-linear effect of body size and maturation

Pharmacokinetics, safety, tolerability, and antiviral activity of dolutegravir dispersible tablets in infants and children with HIV-1 (IMPAACT P1093): results of an open-label, phase 1–2 trial

Abacavir dosing in neonates from birth to 3 months of life: a population pharmacokinetic modelling and simulation study

Rilpivirine Pharmacokinetics Without and With Darunavir/Ritonavir Once Daily in Adolescents and Young Adults

Prioritising the most needed paediatric antiretroviral formulations: the PADO4 list

Pharmacokinetics of Unboosted Atazanavir in Treatment-experienced HIV-infected Children, Adolescents and Young Adults

Efavirenz Concentrations and Probability of HIV Replication in Children

Pharmacokinetics of Nevirapine in HIV and Tuberculosis–coinfected Children Receiving Antiretroviral Fixed-dose Combination Tablets While Receiving Rifampicin-containing Tuberculosis Treatment and After Rifampicin Discontinuation

Plasma efavirenz concentrations and the association with CYP2B6―516G>T polymorphism in HIV―infected Thai children

A Chewable Pediatric Fixed-dose Combination Tablet of Stavudine, Lamivudine, and Nevirapine: Pharmacokinetics and Safety Compared With the Individual Liquid Formulations in Human Immunodeficiency Virus-infected Children in Thailand

Aktive Filter

Suchergebnisse filtern